Trial Profile

A Phase I/II Study of the JAK1/2 Inhibitor Ruxolitinib for Relapsed / Refractory Immune Bone Marrow Failure

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ruxolitinib (Primary)
Indications Anaemia; Aplastic anaemia; Bone marrow aplasia; Bone marrow disorders; Febrile neutropenia; Large granular lymphocytic leukaemia; Myelodysplastic syndromes; Neutropenia; Pure red cell aplasia; Thrombocytopenia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

10 Dec 2024 Study Design and Methods, presented at the 66th American Society of Hematology Annual Meeting and Exposition
21 Feb 2024 Planned initiation date (estimated date for recruitment of the first subject) changed to 27 Feb 2024.
25 Jan 2024 Planned initiation date (estimated date for recruitment of the first subject) changed from 29 Jan 2024 to 5 Feb 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com